DADC
AXSM icon

D.A. Davidson & Co’s Axsome Therapeutics AXSM Stock Holding History

D.A. Davidson & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Sell
5,875
-170
-3% -$36.9K 0.01% 852
2026
Q1 		$1.02M Sell
6,045
-135
-2% -$23.3K 0.01% 922
2025
Q4 		$1.13M Hold
6,180
– – 0.01% 848
2025
Q3 		$751K Sell
6,180
-475
-7% -$53.5K ﹤0.01% 976
2025
Q2 		$695K Sell
6,655
-100
-1% -$10.6K ﹤0.01% 931
2025
Q1 		$788K Sell
6,755
-1,475
-18% -$168K 0.01% 856
2024
Q4 		$696K Buy
8,230
+70
+0.9% +$6.44K 0.01% 902
2024
Q3 		$733K Sell
8,160
-1,255
-13% -$110K 0.01% 880
2024
Q2 		$758K Buy
9,415
+375
+4% +$27.8K 0.01% 831
2024
Q1 		$721K Buy
9,040
+1,800
+25% +$151K 0.01% 845
2023
Q4 		$576K Sell
7,240
-190
-3% -$12.7K 0.01% 902
2023
Q3 		$519K Sell
7,430
-15
-0.2% -$1.12K 0.01% 895
2023
Q2 		$535K Sell
7,445
-75
-1% -$5.53K 0.01% 909
2023
Q1 		$464K Sell
7,520
-2,410
-24% -$158K 0.01% 913
2022
Q4 		$766K Sell
9,930
-850
-8% -$50.8K 0.01% 710
2022
Q3 		$481K Sell
10,780
-4,400
-29% -$220K 0.01% 829
2022
Q2 		$581K Buy
15,180
+170
+1% +$5.38K 0.01% 777
2022
Q1 		$621K Buy
15,010
+675
+5% +$20.9K 0.01% 800
2021
Q4 		$542K Sell
14,335
-1,990
-12% -$73.2K 0.01% 852
2021
Q3 		$538K Buy
16,325
+6,990
+75% +$272K 0.01% 819
2021
Q2 		$630K Buy
9,335
+355
+4% +$21.3K 0.01% 767
2021
Q1 		$508K Buy
8,980
+1,775
+25% +$125K 0.01% 803
2020
Q4 		$587K Buy
7,205
+205
+3% +$15.3K 0.01% 653
2020
Q3 		$499K Buy
7,000
+3,105
+80% +$242K 0.01% 619
2020
Q2 		$320K Buy
+3,895
New +$300K 0.01% 730
2020
Q1 		– Sell
-3,550
Closed -$367K – 993
2019
Q4 		$367K Buy
+3,550
New +$143K 0.01% 761

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.A. Davidson & Co's AXSM Position: Q2 2026 in Review

D.A. Davidson & Co reduced its Axsome Therapeutics (AXSM) stake by 2.8% in Q2 2026, selling an estimated $36.9K and leaving 5,875 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #852.

D.A. Davidson & Co first reported a position in AXSM in Q4 2019 and has held it in 26 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • D.A. Davidson & Co held 5,875 shares of Axsome Therapeutics worth $1.44M as of Q2 2026.
  • D.A. Davidson & Co sold 170 Axsome Therapeutics shares in Q2 2026, an estimated $36.9K.
  • Axsome Therapeutics made up 0.01% of D.A. Davidson & Co's portfolio in Q2 2026, its #852 holding.
  • D.A. Davidson & Co first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.